HomeQuestion

Would you recommend adding Debio 1143 to high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck?

1 Answers

Mednet Member

Medical Oncology · Karmanos Cancer Institute, Wayne State University

At this point, I will still refer LAHNSCC patients to the phase-3 clinical trial randomizing patients to placebo vs Debio-1143.

Would you recommend adding Debio 1143 to high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck? | Mednet